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Abstract. Uterine cervical adenocarcinoma has a poor 
clinical prognosis when compared with squamous cell 
carcinoma. Therefore, the development of new treatment 
strategies for uterine cervical adenocarcinoma is necessary. 
Src is a proto-oncogene that is important in cancer progres-
sion. Dasatinib is a Src inhibitor that has been reported to be 
effective when used in combination with anticancer drugs. 
The present study aimed to confirm Src expression in human 
cervical adenocarcinoma cell lines and to determine the 
mechanism underlying the inhibitory effect of dasatinib on 
Src signaling in vitro. Western blot analysis was performed 
to investigate Src expression in cervical adenocarcinoma 
cell lines (HeLa and TCO-2 cells). The cells were cultured 
for 48 h with the addition of different concentrations of anti-
cancer drugs (paclitaxel or oxaliplatin). Viable cell count was 
measured using a colorimetric (WST-1) assay. The concentra-
tions of anticancer agents were fixed according to the results 
obtained, and the same experiments were performed using the 
drugs in combination with dasatinib at various concentrations 
to determine the concentrations that significantly affected the 
number of viable cells. The presence or absence of apoptosis 
was investigated using a caspase-3/7 assay. Signal transduc-
tion in each cell line was examined using western blotting. Src 
was activated in the two cell lines, and cell proliferation was 
significantly suppressed by each anticancer drug in combina-
tion with 10 µM dasatinib. Caspase-3/7 activity was also 
increased and Src signaling was suppressed by each anticancer 
drug in combination with dasatinib. In conclusion, Src is over-
expressed in cervical adenocarcinoma cell lines, and dasatinib 
inhibits intracellular Src signaling and causes apoptosis. The 
results of the present study suggest that Src may be targeted in 
novel therapeutic strategies for cervical adenocarcinoma.
Introduction
In 2011, more than 10,000 women in Japan were diagnosed 
with uterine cervical carcinoma and almost 2,900 succumbed 
to this disease (1). The major histopathological type of 
cervical cancer is squamous cell carcinoma, and the second 
most frequent type is adenocarcinoma, accounting for 15-20% 
of cases (2). The incidence of cervical adenocarcinoma is 
increasing, and its prognosis is poor compared with that of 
squamous cell carcinoma due to its low response to chemo-
therapy and radiotherapy (1,3). According to the National 
Comprehensive Cancer Network guidelines, treatment of 
cervical cancer is stratified by stage (3). However, the same 
treatment is used for adenocarcinoma and squamous cell 
carcinoma of the cervix (4). Therefore, a novel therapy for 
cervical adenocarcinoma is required.
Src is a non-receptor tyrosine kinase protein that inter-
acts with receptor tyrosine kinases. Src binds its own Src 
homology 2 (SH2) domain with a short peptide sequence 
containing phosphorylated tyrosine (Tyr 530) at the C-terminal 
tail, and SH3 is coupled with the proline-rich linker domain. 
SH2 and SH3 inactivate the structure of the metabolic region. 
When Tyr 530 is dephosphorylated, intramolecular interac-
tion is destabilized, leading to autophosphorylation of Tyr 419 
and activation of Src (5). Src is an important factor in cell 
survival, proliferation, angiogenesis and metastasis (5,6). Src 
family kinases are frequently overexpressed and activated 
in a variety of epithelial and non-epithelial cancers and 
contribute to resistance to chemotherapy (7). Thus, Src is 
being investigated for molecularly targeted therapy in cervical 
adenocarcinoma.
Dasatinib is an inhibitor of the Src family of tyrosine 
kinases and of the Bcr-Abl tyrosine kinase (4,5). It was 
originally approved as a drug for the treatment of chronic 
myeloid leukemia and Philadelphia chromosome-positive 
acute lymphoblastic leukemia (4,5). Clinical trials have been 
conducted using dasatinib in combination with anticancer 
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drugs for the treatment of breast, colon, prostate and other 
cancers (8-17). Single‑agent dasatinib has not exhibited any 
clinical activity in breast, pancreatic, colorectal and ovarian 
carcinoma (8,12,13,15). However, combination therapy with 
dasatinib and anticancer drugs has been demonstrated to be 
clinically effective in the treatment of breast, prostate, ovarian 
and pancreatic cancers (9-11,14,16,17).
A number of studies have reported Src expression in cervical 
cancer (18-22). However, data are lacking on its expression in 
cervical adenocarcinoma. The present study aimed to confirm 
Src expression in human cervical adenocarcinoma cell lines 
and to determine the mechanism of inhibition of Src signaling 
by dasatinib in vitro.
Materials and methods
Cell lines and cultures. HeLa (RCB0007) and TCO-2 
(RCB0689) cells were cultured in Eagle's minimum essential 
medium (Wako Pure Chemical Industries, Ltd., Osaka, Japan), 
supplemented with 10% fetal bovine serum (Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) and 1% penicillin‑strep-
tomycin solution in 5% CO2 at 37˚C. These cell lines were 
derived from women with uterine cervical adenocarcinoma, 
and were provided by the RIKEN BioResource Center 
(Tsukuba, Japan) through the National Bio-Resource Project 
of the Japanese Ministry of Education, Culture, Sports, 
Science and Technology (MEXT). In vitro experiments were 
conducted with subconfluent cells.
Drugs and reagents. Anti-Src (cat. no. 2109), anti-phospho 
(p)-Akt (cat. no. 9271S), anti-p-p44/42 MAPK (Erk1/2) 
(cat. no. 9101) and anti-β-actin (cat. no. 4967) antibodies 
for western blotting were all purchased from Cell Signaling 
Technology, Inc. (Danvers, MA, USA). Anti-p-Src Y419 
(cat. no. AF2685) was purchased from R&D Systems, Inc. 
(Minneapolis, MN, USA). Dasatinib (Focus Biomolecules, 
Plymouth Meeting, PA, USA) was prepared as a 10-mmol/l 
stock solution in dimethyl sulfoxide (DMSO). Paclitaxel 
was purchased from Bristol-Myers Squibb (New York, NY, 
USA) and oxaliplatin was purchased from AdooQ Bioscience 
(Irvine, CA, USA).
Cytotoxicity assays. The cytotoxicity of paclitaxel, oxali-
platin and the combination of each of these drugs with 
dasatinib in HeLa and TCO‑2 cells was examined using the 
Cell Proliferation reagent WST-1 (Roche Applied Science, 
Penzberg, Germany) according to the manufacturer's instruc-
tions. The cells were seeded in 96-well plates (5,000 cells/well) 
with serum-containing medium and incubated for 24 h. The 
medium was then replaced with 100 µl fresh serum free 
medium containing various concentrations of drug: Paclitaxel 
(0, 0.0005, 0.001, 0.005, 0.01, 0.05, 1 and 10 µg/ml), oxaliplatin 
(0, 0.1, 0.5, 1, 5, 10, 50, 100 and 500 µg/ml), and dasatinib 
(0, 0.0001, 0.001, 0.01, 0.1, 1, 10 and 100 µM). Treatment was 
stopped at 48 h, and the WST-1 reagent was added to each 
well. Following a 2‑h incubation period at 37˚C and 5% CO2, 
the absorbance at 450 nm of the samples against a background 
control as blank was measured using a microplate reader 
(Thermo Fisher Varioskan Flash; Thermo Fisher Scientific, 
Inc.). Each sample was analyzed in triplicate.
Apoptosis assay. For evaluation of apoptosis, caspase-3/7 
activity was measured. The cells were plated at 5,000 cells/well 
in black 96-well plates and incubated for 24 h. The cells were 
then treated with either paclitaxel (0.005 µg/ml) or oxaliplatin 
(5 µg/ml) in the presence or absence of dasatinib (10 µM) 
for 48 h. Following the treatment, 100 µl reagent from the 
Apo-ONE Homogeneous Caspase-3/7 assay kit (Promega 
Corporation, Fitchburg, WI, USA) was added to each well, 
which contained 100 µl blank, control or treated cells in culture. 
The plates were gently mixed with a plate shaker at 500 rpm 
for 30 sec. The fluorescence of each well was measured using 
a microplate reader (Thermo Fisher Varioskan Flash) with a 
480/520 excitation/emission filter and a gain setting of 25.
Western blotting. Cells were harvested to 80% confluence, and 
dasatinib and anticancer agents were added as indicated. Cells 
were lysed in M‑PER Mammalian Protein Extraction reagent 
(Thermo Fisher Scientific, Inc.). Protein concentrations were 
measured with a Pierce BCA Protein Assay kit (Thermo 
Fisher Scientific, Inc.). The total protein (10 µg) was separated 
by 7.5% SDS-PAGE and transferred electrophoretically onto a 
polyvinylidene difluoride membrane. The blots were blocked 
for 3 h at room temperature with 3% bovine serum albumin 
(Wako Pure Chemical Industries, Ltd.) and then probed with 
the aforementioned primary antibodies in TBST (1:1,000) 
at 4˚C overnight. Secondary antibody binding was conducted 
by incubating the blots with peroxidase‑conjugated AffiniPure 
Goat Anti-Rabbit IgG (H+L) from Jackson ImmunoResearch 
Laboratories, Inc. (West Grove, PA, USA) at a dilution of 
1:10,000 for 1 h at room temperature. Proteins were visualized 
by incubation with ECL Prime Western Blotting Detection 
reagent (GE Healthcare, Little Chalfont, UK) and detected 
with an image analyzer (LAS Amersham Imager 600; 
GE Healthcare). Anti-β-actin antibody was used as a positive 
control. Densitometry was performed to interpret differences 
in the results using ImageJ software version 1.51 (National 
Institutes of Health; Bethesda, MD, USA).
Statistical analysis. Statistical analyses were performed using 
SPSS software, version 20 (IBM Corp., Armonk, NY, USA). 
Inhibition of cell growth by anticancer agents and/or dasatinib 
was evaluated using Dunnett's test. One-way analysis of vari-
ance with Bonferroni's adjustment was used for the caspase-3/7 
assay. DMSO was used for comparison as a negative control. 
All experiments were performed in triplicate. All P‑values 
were two-sided, and P<0.05 was considered to indicate a 
statistically significant difference in all statistical analyses.
Figure 1. Src and p‑Src (Tyr 416) expression in HeLa and TCO‑2 cell lines. 
Protein levels were examined using western blot analysis.
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Results
Src and p‑Src protein expression in cervical adenocarcinoma 
cell lines. Src kinase protein expression was evaluated in two 
cervical adenocarcinoma cell lines using western blot analysis 
(Fig. 1). The two cell lines clearly exhibited Src and p‑Src 
expression. The TCO‑2 cell line exhibited higher expression 
levels of Src and p-Src than did the HeLa cell line.
Figure 3. Suppressive effect of anticancer agents on cell proliferation in HeLa and TCO-2 cell lines. Cell viability assays were conducted to determine the 
viability of HeLa and TCO‑2 cell lines following treatment with (A) paclitaxel and (B) oxaliplatin for 48 h. (A) *P<0.05 vs. the 0 µg/ml paclitaxel group; 
(B) *P<0.05 vs. the 0 µg/ml oxaliplatin group. Results are presented as the mean ± standard error of the mean.
Figure 2. Suppressive effect of dasatinib on cell proliferation in HeLa and TCO-2 cell lines. Cell viability assays were conducted following treatment of 
(A) HeLa and (B) TCO-2 cell lines with dasatinib for 48 h. *P<0.05 vs. the 0 µM dasatinib group. Results are presented as the mean ± standard error of the 
mean.
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Combinations of dasatinib and anticancer drugs significantly 
suppress the proliferation of cervical adenocarcinoma cells. 
The cytotoxic effect of dasatinib was investigated in HeLa and 
TCO-2 cells using a WST-1 assay. The effect of treatment with 
various concentrations of dasatinib (0, 0.0001, 0.001, 0.01, 0.1, 
1, 10 and 100 µM) on cell survival in the two cell lines was 
evaluated. Cell proliferation was significantly suppressed by 
treatment with ≥10 µM dasatinib compared with that in the 
control group treated with DMSO only (Fig. 2).
The cytotoxicity of paclitaxel and oxaliplatin was also 
investigated in the HeLa and TCO-2 cell lines. Treatment with 
each drug suppressed cell growth in a dose-dependent manner 
(Fig. 3). Based on these results, the concentrations of paclitaxel 
and oxaliplatin were fixed (paclitaxel 0.005 µg/ml, oxaliplatin 
5 µg/ml) as they were the highest concentrations that did not 
have a cytotoxic effect, and various concentrations of dasatinib 
were used with each of the two anticancer drugs. In all cases, 
when compared with the group receiving the anticancer drug 
alone (control), a significant difference was observed with the 
use of ≥10 µM dasatinib (Fig. 4). Therefore, a decision was 
made to culture the cells with 10 µM dasatinib and collect the 
protein for analysis.
Combination of dasatinib with anticancer agents causes 
apoptosis in HeLa and TCO‑2 cells. The activity of casp-
ase-3/7 was measured using a caspase-3/7 assay kit in order 
to investigate the apoptosis associated with combination 
treatment (Fig. 5). The anticancer drug alone, dasatinib alone, 
and the anticancer drug plus dasatinib combination groups 
were compared to determine whether there were differences 
between the groups. The induction of caspase-3/7 was signifi-
cantly increased in the combination group when compared 
with control group (DMSO only), suggesting the induction of 
cell death by apoptosis.
Combination of dasatinib with anticancer agents inhibits the 
level of p‑Src expression and downstream signal transduction. 
Src signaling was investigated, with the use of western blot 
analysis to evaluate p‑Src, p‑Akt, and p‑Erk expression 
(Fig. 6). When dasatinib was used in combination with an 
Figure 4. Suppressive effect of dasatinib and anticancer drug combinations on cell proliferation in HeLa and TCO-2 cell lines. Cell viability assays for the combi-
nation of (A) PTX and DAS and (B) L-OHP and DAS in HeLa and TCO-2 cell lines following treatment for 48 h. (A) *P<0.05 vs. the 0 µM DAS + 0.005 µg/ml 
PTX group; (B) *P<0.05 vs. the 0 µM DAS + 5 µg/ml L‑OHP group. Results are presented as the mean ± standard error of the mean. PTX, paclitaxel; 
DAS, dasatinib; L‑OHP, oxaliplatin.
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anticancer agent, the Src phosphorylation was suppressed, and 
phosphorylation in the downstream Akt and MAPK pathways 
was also inhibited (4).
Discussion
The purpose of this study was to confirm Src expression in 
human cervical adenocarcinoma cell lines and to determine 
the mechanism underlying the inhibition of Src signaling 
by dasatinib at the cellular and protein levels. The present 
authors performed an immunohistochemical analysis to reveal 
Src expression in human adenocarcinoma cells. A total of 
49 specimens were obtained from patients who underwent 
surgery between 2001 and 2011 at the Tokushima University 
Hospital (Tokushima, Japan). In the normal cervical gland 
tissue, Src expression was not observed (0/12). In the invasive 
cervical adenocarcinoma tissue, the expression rate of Src was 
44% (16/36), which was significantly higher than that in the 
normal cervical gland tissue (data not shown). This demon-
strated that Src was expressed in human adenocarcinoma 
cell lines. In HeLa and TCO-2 cell lines, cell proliferation 
was significantly suppressed and apoptosis was significantly 
induced by dasatinib in combination with paclitaxel or 
oxaliplatin in the present study. Dasatinib in combination with 
paclitaxel or oxaliplatin suppressed Src phosphorylation and 
also suppressed downstream signaling via the Akt and MAPK 
pathways, as determined by western blot analysis. These 
results support the hypothesis that Src is expressed in cervical 
adenocarcinoma and that antitumor drugs become more effec-
tive when Src signaling is inhibited.
Uterine cervical carcinoma is one of the most serious 
diseases worldwide, and surgery, chemotherapy and radio-
therapy have been used to treat it (2,4). Patients in the advanced 
stage in various solid tumors show resistance to treatment, and 
a number of studies have investigated novel antitumor agents, 
with a particular focus on molecularly targeted drugs. In recent 
years, Src inhibitors have been studied extensively (8-17).
Clinical trials have revealed no effect of dasatinib alone 
on breast, pancreatic, colorectal and ovarian tumor progres-
sion, overall survival or progression-free survival (8,12,13,15). 
This may be due to the activation of other signaling molecules, 
such as the Src family kinases Janus kinase and FGR (14). 
However, combination therapy with dasatinib and anticancer 
drugs has been found to be effective for inhibiting tumor 
growth (9-11,14,16,17). These results are consistent with a 
number of in vitro experiments (18-22) and the present study.
Figure 5. Effect of dasatinib and anticancer agents, alone or in combination, on caspase-3/7 in HeLa and TCO-2 cells. Cells were treated with (A) DAS 
(10 µM) or PTX (0.005 µg/ml) alone, or in combination, or with (B) DAS (10 µM) or L-OHP (5 µg/ml) alone, or in combination for 48 h and compared with 
an untreated control group. Caspase-3/7 activities were measured. *P<0.05 vs. the untreated control. Results are presented as the mean ± standard error of the 
mean. PTX, paclitaxel; DAS, dasatinib; L‑OHP, oxaliplatin.
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Mucinous ovarian carcinoma is resistant to oxaliplatin; 
however, this resistance was diminished when dasatinib was 
used in combination with oxaliplatin (17). Combination treat-
ment with dasatinib and paclitaxel has a synergistic effect 
against cancer through Src signaling (19). The Src inhibitor 
PP2 has been shown to inhibit cervical cancer cell proliferation 
via the downregulation of p-Src (23), and p-Src is a predictor 
of relapse of squamous cell carcinoma (24). However, to the 
best of our knowledge, the effect of Src inhibitors on adeno-
carcinoma of the uterine cervix has not been reported, and the 
present study is the first of its kind to delineate Src expression 
in cervical adenocarcinoma.
In HeLa and TCO-2 cell lines, cell proliferation was signif-
icantly suppressed by ≥10 µM dasatinib alone. When dasatinib 
Figure 6. Western blotting results showing p‑Src, p‑Akt and p‑Erk expression in HeLa and TCO‑2 cells treated with (A) dasatinib (10 µM) or PTX (0.005 µg/ml) 
alone or in combination, or with (B) dasatinib (10 µM) or L‑OHP (5 µg/ml) alone or in combination for 48 h. PTX, paclitaxel; DAS, dasatinib; L‑OHP, oxali-
platin; p, phospho.
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was combined with a non‑cytotoxic concentration of pacli-
taxel or oxaliplatin, ≥1 µM dasatinib significant suppressed 
cell proliferation in the majority of cases. This indicates that 
combining dasatinib with an anticancer drug enhances the 
suppression of cell growth.
In the present study, western blotting results indicated that not 
all the phosphorylated proteins tested (p-Src, p-Akt and p-Erk) 
were activated by paclitaxel or oxaliplatin alone compared with 
controls. However, the anticancer agents alone also did not reliably 
suppress the activation of phosphorylated proteins, suggesting 
that they alone do not necessarily increase resistance. Cervical 
adenocarcinoma cells may respond in a different manner than 
do mucinous ovarian cancer cells. Although the concentrations 
of dasatinib used in the experiments in the present study were 
not sufficient to suppress the expression of the phosphorylated 
proteins, suppression was observed when dasatinib was used in 
combination with an anticancer agent compared with the control. 
The results indicate that Src signaling may be suppressed by 
combining an anticancer agent with dasatinib. However, the 
effect of the suppression of Src in vivo is unclear. Further studies 
are required to identify the mechanism underlying the effects of 
dasatinib in animal models.
In conclusion, Src is expressed in cervical adenocarcinoma 
cell lines. Dasatinib inhibits intracellular Src signaling and 
causes apoptosis. The results of the present study suggest that 
anti-Src molecularly targeted therapy may be used as a novel 
treatment strategy for cervical adenocarcinoma.
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